With RxData, conduct your analogue analysis with peace of mind! Clear information with holistic views of key product life-cycle events:
With live monitoring of more than 100 data sources, RxData is the most complete repository of market access intelligence. RxData has detailed market access information presented in a simple way.
Better assess and predict coverage across U.S. payer types:
Better evaluate global decisions:
With RxData, go-to-market faster:
Find out about any changes in restrictiveness quarter by quarter. Search and filter through over 200,000 entries for a given drug, geography or payer for changes in Tier, Prior Authorization, Step Edits or Quantity Limit requirements.
Find out about the evolution of labels over time by diving deep into FDA's Structured Product Labels in effect since 2005. Find out about indication extensions via MeSH headings tracked in real-time. Reach out to us if you are interested in our RxData Labels FDA API.
Phase 2/3 Transition (1)
Company A has a small molecule that has demonstrated activity across a range of tumors in Phase 2 and is finalizing Phase 3 strategy. Ultimately the company is looking to maximize lifetime value of the asset. The company intends to model the value of each potential indication (accounting for potential price, size of opportunity and competitive intensity) and then analyze whether lifetime value is enhanced by sequencing smaller but higher priced indications first vs. focusing on the largest potential indication.